Ozone therapy as a novel complementary therapeutic approach in refractory idiopathic granulomatous mastitis.
idiopathic granulomatous mastitis
ozone therapy
refractory granulomatous mastitis
steroid
steroid resistance
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
04
2023
accepted:
16
06
2023
medline:
24
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Autoimmunity may play a major role in the pathogenesis of idiopathic granulomatous mastitis (IGM). The therapeutic potential of ozone therapy has recently been shown in rheumatological diseases, and this study aimed to assess the clinical efficacy of ozone therapy (OT) in refractory IGM. Patients with biopsy-verified IGM and incomplete response after steroid therapy ( The median age was 33 years (range, 24-45). Patients in cohort B had a higher complete response rate after completion of a four-month ozone therapy than those in the ST-group (OT-group, 37.5% vs. ST-group, 0%; Systemic OT increases the complete response rate and decreases the duration of steroid treatment in patients with refractory IGM. Therefore, ozone therapy is an effective, well-tolerated, and safe novel complementary therapeutic modality.
Sections du résumé
Background
UNASSIGNED
Autoimmunity may play a major role in the pathogenesis of idiopathic granulomatous mastitis (IGM). The therapeutic potential of ozone therapy has recently been shown in rheumatological diseases, and this study aimed to assess the clinical efficacy of ozone therapy (OT) in refractory IGM.
Methods
UNASSIGNED
Patients with biopsy-verified IGM and incomplete response after steroid therapy (
Results
UNASSIGNED
The median age was 33 years (range, 24-45). Patients in cohort B had a higher complete response rate after completion of a four-month ozone therapy than those in the ST-group (OT-group, 37.5% vs. ST-group, 0%;
Conclusion
UNASSIGNED
Systemic OT increases the complete response rate and decreases the duration of steroid treatment in patients with refractory IGM. Therefore, ozone therapy is an effective, well-tolerated, and safe novel complementary therapeutic modality.
Identifiants
pubmed: 37484853
doi: 10.3389/fmed.2023.1174372
pmc: PMC10357005
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1174372Informations de copyright
Copyright © 2023 Cabioglu, Trabulus, Emiroglu, Ozkurt, Yalcin, Dinc, Tukenmez, Muslumanoglu, Igci, Ozmen, Dinccag and Guven.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Pharmacol. 2016 Oct 15;789:313-318
pubmed: 27450487
Clin Rheumatol. 2020 May;39(5):1671-1677
pubmed: 31916110
Anim Reprod Sci. 2015 Aug;159:1-7
pubmed: 26059777
World J Surg. 2019 Nov;43(11):2865-2873
pubmed: 31297582
Int J Mol Sci. 2021 Jul 23;22(15):
pubmed: 34360655
Oxid Med Cell Longev. 2014;2014:273475
pubmed: 25089169
Medicine (Baltimore). 2020 May 29;99(22):e20457
pubmed: 32481453
Surgeon. 2022 Jun;20(3):e13-e19
pubmed: 33836950
Surg J (N Y). 2021 Sep 14;7(3):e226-e236
pubmed: 34541314
Breast Care (Basel). 2022 Apr;17(2):172-179
pubmed: 35707181
Breast Care (Basel). 2020 Feb;15(1):60-66
pubmed: 32231499
Acta Cir Bras. 2016 Apr;31(4):256-63
pubmed: 27168538
Immunol Invest. 2022 Feb;51(2):357-367
pubmed: 33034215
Breastfeed Med. 2017 Sep;12(7):415-421
pubmed: 28731822
Gland Surg. 2019 Dec;8(6):712-722
pubmed: 32042679
Rheumatol Int. 2023 Mar;43(3):399-407
pubmed: 36418558
Breast Cancer Res Treat. 2010 Sep;123(2):447-52
pubmed: 20625813
Surg Today. 2015 Apr;45(4):457-65
pubmed: 24993812
Breast Care (Basel). 2014 Oct;9(5):338-42
pubmed: 25759614
Breast Care (Basel). 2014 May;9(2):111-5
pubmed: 24944554
Breast J. 2005 Mar-Apr;11(2):108-14
pubmed: 15730456
Int Wound J. 2022 May;19(4):853-870
pubmed: 34612569
Eur J Pharmacol. 2013 Aug 15;714(1-3):318-24
pubmed: 23911887
Arch Oral Biol. 2020 Nov;119:104889
pubmed: 32911119
Breast Care (Basel). 2018 Dec;13(6):413-418
pubmed: 30800035
Cell Biol Int. 2023 Jan;47(1):228-237
pubmed: 36378588
Am J Clin Pathol. 1972 Dec;58(6):642-6
pubmed: 4674439
J Invest Surg. 2022 Feb;35(2):325-329
pubmed: 33327830
J Vet Med Sci. 2000 Jul;62(7):681-6
pubmed: 10945283
J Vet Med Sci. 2006 Feb;68(2):175-8
pubmed: 16520542